Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Severe Asthma
Interventions
Hyperpolarized Xenon 129
Combination Product
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Hyperpolarized xenon MRI
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer
Drug · Device
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Cystic Fibrosis
Interventions
hyperpolarized Xenon gas
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
20 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Early Phase 1 Interventional Accepts healthy volunteers

Image and Model Based Analysis of Lung Disease

NCT03764163
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Pulmonary Function Test, CT Scans, Questionnaires, MRI, Xenon gas
Diagnostic Test · Behavioral · Biological
Lead sponsor
Eric A. Hoffman
Other
Eligibility
20 Years to 89 Years
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Pulmonary Surgical Procedures
Interventions
129Xe MRI, 133 Xe scintigraphy
Drug
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Cincinnati, Ohio • Charlottesville, Virginia
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration

NCT02316379
Conditions
Respiratory Disorders
Interventions
Hyperpolarized 129 Xenon, MRI
Drug · Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2032
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Lung Transplant Rejection
Interventions
Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Thoracic Insufficiency Syndrome
Interventions
Xenon-129
Device
Lead sponsor
Patrick Cahill, MD
Other
Eligibility
6 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cystic Fibrosis
Interventions
Xenon MRI
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Active, not recruiting Phase 4 Interventional

Hyperpolarized Imaging for New Treatments

NCT04259970
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Enrolling by invitation Phase 1Phase 2 Interventional Accepts healthy volunteers

Technical Development of Xe MRI

NCT07823010
Conditions
HSCT, Lung Transplant Recipient
Interventions
Hyperpolarized 129 Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Asthma, COPD, Healthy
Interventions
HXe MRI lung ventilation
Drug
Lead sponsor
Xemed LLC
Industry
Eligibility
21 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Pulmonary Arterial Hypertension
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Phase 2 Interventional Results available

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

NCT04071769
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting Phase 2 Interventional

Pulmonary Hypertension SOLAR

NCT04778046
Conditions
Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

NCT06856525
Conditions
Electronic Cigarette Related Lung Damage
Interventions
Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT
Drug · Diagnostic Test
Lead sponsor
Y. Michael Shim, MD
Other
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Conditions
Asthma
Interventions
HXe MRI guided treatment sequence for BT, Standard treatment sequence for BT (control)
Drug · Other
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Withdrawn Phase 1 Interventional Accepts healthy volunteers

129Xe MRI in Pediatric Population With BPD

NCT04035629
Conditions
Bronchopulmonary Dysplasia
Interventions
MagniXene, hyperpolarized 129Xe MRI
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
Up to 1 Year
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting Phase 2 Interventional

Xenon MRI and Progressive ILD

NCT05241275
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting No phase listed Observational Accepts healthy volunteers

Regional Phenotyping of CF and Non-CF Bronchiectasis

NCT04793867
Conditions
Cystic Fibrosis, Non-CF Bronchiectasis
Interventions
Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Covid19
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas